Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro – Owkin's AI Scientist for biopharma decision making. K Pro brings multimodal data and specialized biological agentic AI to each step of the value chain. Under the three-year licensing agreement, Owkin will lead the.

LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it has been selected for a poster presentation of the BI-1206 triplet combination in relapsed/refractory non-Hodgkin's lymphoma (NHL) at the 31st European Hematology Association (EHA2026) Congress, taking place June 11-14, 2026 in Stockholm, Sweden. Poster Presentation Title: Targeting resistance to rituximab through FcγRIIB (CD32B) blockade: BI-1206 + rituximab + acalabrutinib shows powerful activity in R/R NHL Presenter: Dr. Laura Fogliatto, Hospital de Clínicas de Porto Alegre, Brazil Session Date/Time: Friday, June 12, 6:45 pm-7:45 pm CEST (12:45 pm-1:45 pm EDT) Location: EHA2026 Congress, Stockholm The presentation will summarize emerging efficacy and safety observations and mechanistic insights from the ongoing Phase 1/2 study (NCT03571568) evaluating BI-1206 in combination with rituximab and Calquence® (acalabrutinib) in patients with relapsed or refractory NHL, including follicular lymphoma.

In Q1 2026, Polen International Growth Portfolio returned -14.4% (net of fees) compared to -0.7% for the Index. We initiated new positions in TSMC, Rheinmetall, Saab, Mitsubishi Heavy Industries, AstraZeneca, AIA Group, Siemens Energy, Samsung Electronics, and Keyence. We sold our holdings in Nintendo, MakeMyTrip, Adidas, Globant, Amadeus IT Group, Monday.com, ICON plc, and HDFC Bank.

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.

AbbVie ABBV stock has risen around 5% since it announced robust first-quarter 2026 results on April 29. It beat estimates for both earnings and sales and the guidance for 2026 revenues and earnings was also raised.

Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely needed tailwind for the healthcare sector.

An advisory panel for the U.S. Food and Drug Administration voted 6-3 against AstraZeneca's oral drug camizestrant intended for a type of breast cancer tumor, citing concerns around trial design. AstraZeneca's London-listed shares fell on the back of the vote outcome.